CVS Health vs. UnitedHealth: Comparing Revenue Trends for These Healthcare Companies

CVS Health and UnitedHealth both saw steady revenue growth through late 2025, but posted slight sequential declines in early 2026, raising the question of whether the contraction is temporary. For the quarter ended March 2026, CVS generated $100.4B revenue (about 3% net income margin) and UnitedHealth generated $111.7B revenue (about 6% net income margin), with CVS showing stronger YoY growth (+6% vs. UNH +2%). Despite the early-2026 dip, both companies raised full-year guidance, signaling expectations for a strong year ahead.

Analysis

The important signal is not the revenue level; it is the spread between top-line scale and profit quality. UNH’s slower growth but materially higher net margin implies better pricing power and tighter control over medical cost leakage, so the equity should keep commanding the cleaner earnings multiple even if the market fixates on headline growth. CVS’s mix remains more fragile: retail/pharmacy volume is cyclical and low margin, so revenue resilience does not automatically translate into EPS leverage.

The near-term catalyst path is mostly about medical-loss and utilization data, not sales. UNH’s easing of prior-authorization friction could improve provider relations and retention, but it also risks incrementally higher utilization over the next 1-2 quarters; if that shows up in MLR, the market will re-rate the stock quickly. For CVS, the Omnicare exit is more of a complexity-reduction story than an earnings inflection unless management can show cash-flow conversion and margin expansion after the divestiture.

Consensus may be overvaluing the “CVS caught up on revenue” narrative and undervaluing the fact that mature healthcare roll-ups often win through spread capture, not growth. The more interesting second-order loser is the generic retail-pharmacy ecosystem: if CVS keeps prioritizing profitability over volume, weaker peers like WBA face less room to defend script share. Falsify the bullish UNH view if net margin slips back toward the low-5% area or guidance is cut; falsify the CVS recovery view if sequential revenue weakness persists and gross margin fails to improve through Q2-Q3 2026.

Key Decisions for Investors

• Long UNH / short CVS as a 1-3 month relative-value pair trade; target 8-12% spread outperformance if UNH holds margin leadership and CVS remains stuck near 3% net margin. Exit if UNH medical cost trend worsens or CVS posts two consecutive quarters of margin expansion.
• If seeking defined risk, buy UNH call spreads into the next earnings cycle and finance part of the premium with short-dated CVS puts; this expresses the view that earnings quality, not revenue growth, drives multiple support.
• Treat CVS as a watchlist name, not an outright long: only add on evidence of cash-flow and margin improvement post-Omnicare sale. If that proof does not appear by the next two quarters, assume the revenue story is cosmetic.
• Consider a tactical short in WBA as a second-order retail-pharmacy beneficiary loser if CVS prioritizes margin over share; the risk is a defensive sector rerating if drug volume stabilizes unexpectedly.